PNPernelle Noize

Pernelle Noize

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pernelle Noize has a total of 191 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mesure de l'exposition médicamenteuse en pharmaco-épidémiologie : étude comparative de données issues des bases de remboursement de l'Assurance Maladie française et de données déclaratives

    by Pernelle Noize

    En pharmaco-épidémiologie, la mesure de l’exposition médicamenteuse est fondamentale. Des données déclaratives recueillies par interrogatoire des sujets ou des données extraites des bases de remboursement de l’Assurance Maladie peuvent être utilisées. Les objectifs de ce travail étaient de comparer l’exposition mesurée à partir de ces deux sources de données et d’évaluer l’impact du choix de l’une ou l’autre source sur les mesures de risque dans les études étiologiques. Les travaux ont été conduits au sein de l’étude des Trois-Cités, cohorte de sujets âgés pour laquelle étaient disponibles des données déclaratives et de remboursement. La concordance entre les expositions issues des deux sources ou la validité de l’exposition issue de l’une par rapport à celle issue de l’autre ont été évaluées dans différents contextes. La survenue d’événements a été simulée dans la population et des études cas-témoins nichées ont été conduites pour évaluer l’association entre l’exposition issue de chaque source et chaque événement. Pour les médicaments cardiovasculaires, les mesures d’exposition étaient peu différentes entre les deux sources. L’impact du choix de l’une ou l’autre source sur les mesures d’association entre l’exposition et un événement était faible. Pour les benzodiazépines ou les anti-inflammatoires non stéroïdiens, des différences étaient observées entre les expositions issues des deux sources. Pour ces médicaments, l’association avec un événement pouvait varier selon la source utilisée. Pour des médicaments pris de manière irrégulière ou intermittente, le choix de la source de données pour la mesure de l’exposition peut donc être un élément déterminant.

  • Open Access

    Angiogenesis Inhibitors and Arterial Dissection or Aneurysm in Patients With Metastatic Colorectal Cancer

    by Allison Singier, Ana Jarne Munoz, Sandy Maumus-Robert, Xavier Bérard, Antoine Pariente, Julien Bezin, Emmanuelle Kempf, Pernelle Noize

    Importance: Although pharmacovigilance signals and a strong pathophysiological rationale have suggested a potential risk of arterial dissections or aneurysms associated with angiogenesis inhibitors, this association deserves to be further investigated through clinical practice evidence studies. Objective: To evaluate the association between exposure to angiogenesis inhibitors and the occurrence of arterial dissections or aneurysms in patients treated for metastatic colorectal cancer (mCRC). Design, Setting, and Participants: A nested case-control study was conducted within a cohort of adults initiating targeted therapy (angiogenesis or epidermal growth factor receptor inhibitors) for mCRC between January 1, 2012, and December 31, 2017. Data were analyzed from April 2021 through August 2023. Data were drawn from the French nationwide Système National des Données de Santé database, which combines health insurance and hospital discharge records. Cases of arterial dissection or aneurysm were identified through 2019 and matched with up to 10 controls by age, sex, and time since cohort entry. Exposures: The angiogenesis inhibitors indicated for mCRC in France (ie, bevacizumab, aflibercept, ramucirumab, and regorafenib) were considered. Exposure was defined using 3 criteria: exposure at any point (exposed vs unexposed), recency (current, past, or unexposed), and cumulative duration of exposure (quartiles). Exposure periods were estimated using recommended administration schedules or drug elimination times. Main Outcomes and Measures: The primary outcome was incident hospitalization for arterial dissection or aneurysm, identified through hospital discharge diagnoses. Conditional logistic regression models were applied to estimate the association between exposure to angiogenesis inhibitors and the occurrence of arterial dissections or aneurysms, expressed as odds ratios (ORs) with 95% CIs. Results: Of the 34 733 patients included in the cohort, 195 incident cases (0.6%) were matched with 1950 controls. The study population (2145 patients) included 1562 male patients (72.8%); the median (IQR) age was 69 (63-73) years for cases and 68 (62-73) years for controls. Considering exposure at any point, 141 cases (72.3%) and 1381 controls (70.8%) were exposed to angiogenesis inhibitors; after adjustment for cardiovascular risk level, no association was observed between exposure and the occurrence of arterial events (OR, 1.07; 95% CI, 0.75-1.52). No associations were found with either recency or cumulative duration of exposure, regardless of the exposure estimation method. Conclusions and Relevance: In this case-control study of arterial dissections or aneurysms in patients receiving targeted therapy for mCRC, the lack of association with angiogenesis inhibitor exposure was reassuring, given the established benefits of these drugs, particularly bevacizumab, for this indication.


  • Impact of Cardiovascular Comorbidities on the Effectiveness and Safety of Bevacizumab in Older Patients with Metastatic Colorectal Cancer

    by Amandine Gouverneur, Clélia Favary, Jérémy Jové, Magali Rouyer, Emmanuelle Bignon, Francesco Salvo, Achille Tchalla, Elena Paillaud, Thomas Aparicio, Pernelle Noize

    Background Cardiovascular comorbidities are not contraindications of bevacizumab for metastatic colorectal cancer. Objective We aimed to evaluate the impact of cardiovascular comorbidities before bevacizumab treatment on overall survival and cardiovascular safety in older patients with metastatic colorectal cancer. Methods A 2009–2015 cohort of patients with metastatic colorectal cancer aged ≥ 65 years administered first-line bevacizumab was extracted from the French healthcare reimbursement claims database. Baseline heart failure, hypertension, and venous/arterial thromboembolic events were identified. The 36-month overall survival rate was evaluated using the Kaplan–Meier method, and the impact of cardiovascular comorbidities on the 36-month overall survival using a time-dependent, multivariable, Cox proportional hazards model. The 36-month cumulative incidence of cardiovascular events, and the impact of cardiovascular comorbidities on the likelihood of cardiovascular events were evaluated using the Fine and Gray model, with death as a competing risk. Results We included 9222 patients (56.4% male; median age 73 years). Two-thirds (66.7%) had baseline cardiovascular comorbidities. The median 36-month overall survival was 20.4 [95% confidence interval (CI) 19.9–21.0] and 21.8 [95% CI 21.1–22.6] months in patients with and without cardiovascular comorbidities, respectively. Age ≥ 75 years, dependency in activities of daily living, radiotherapy, and another targeted therapy were identified as death risk factors, but not cardiovascular comorbidities. At 36 months, cardiovascular events had occurred in 60.2% [95% CI 58.9–61.4] and 44.1% [95% CI 42.3–45.9] of patients with and without cardiovascular comorbidities. Baseline venous thrombosis, female, three or more cardiovascular medications, another targeted therapy, and more than six bevacizumab injections were identified as risk factors for cardiovascular events. Conclusions In clinical practice, cardiovascular comorbidities before administering bevacizumab to older patients with metastatic colorectal cancer impacted the cardiovascular safety, but not overall survival. Unless they limit functional independency, older patients with cardiovascular comorbidities should be treated with bevacizumab under close monitoring.


  • Ambulatory drug changes in the elderly after hospital discharge: A cohort study

    by Nicolas Rousselot, Jean-Philippe Joseph, Pernelle Noïze, Driss Berdaï, Annie Fourrier-Réglat, Pauline Bosco-Levy


  • Safety profile of drugs for advanced melanoma: A report based on 2008-2018 US Food and Drug Administration Data

    by Emilie Casarotto, Pernelle Noize, Louis Létinier, Francesco Salvo, Anne Pham‐Ledard, Mathieu Molimard

    We describe the safety profiles of all drug classes used for the treatment of advanced melanoma from the US Food and Drug Administration Adverse Event Reporting System over 2008-2018. Adverse reactions reported in 25 900 pharmacovigilance cases are described for chemotherapies, immunomodulators, targeted therapies and immunotherapies. There was a sharp increase in the number of cases over time, with peaks associated with the launch of new treatments. The adverse reactions diversified over time; notably, skin (alopecias, dermatitis) and retinal disorders were frequently associated with targeted therapies and endocrine disorders (hypothalamus, thyroid and adrenal dysfunctions) with immunotherapies. Less well-known reactions were also detected, such as neuropsychiatric disorders with targeted therapies and gastrointestinal ulcers, pneumothorax and pleural effusions with immunotherapies. The findings highlight the need for various health professionals (including medical specialists or trained nurses) to enhance management of complications.


  • REview of potentially inappropriate MEDIcation pr[e]scribing in Seniors (REMEDI[e]S): French implicit and explicit criteria

    by Barbara Roux, Julie Berthou-Contreras, Jean-Baptiste Beuscart, Marion Charenton-Blavignac, Jean Doucet, Jean-Pascal Fournier, Blandine de la Gastine, Sophie Gautier, Régis Gonthier, Valérie Gras, et al.

    Purpose To establish a consensus on both explicit and implicit criteria in order to identify potentially inappropriate prescribing (PIP) in French older people aged 75 years and over or 65 years and over with multimorbidity. Methods Fifteen experts in geriatrics, general practice, pharmacy, and clinical pharmacology were involved in a two-round Delphi survey to assess preliminary explicit and implicit criteria based on an extensive literature review and up-to-date evidence data. Experts were asked to rate their level of agreement using a 5-level Likert scale for inclusion of criteria and also for rationale and therapeutic alternatives. A consensus was considered as reached if at least 75% of the experts rated criteria as “strongly agreed” or “agreed.” Results The new tool included a seven-step algorithm (implicit criteria) encompassing the three main domains that define PIP (i.e. overprescribing, underprescribing, and misprescribing) and 104 explicit criteria. Explicit criteria were divided into 6 tables related to inappropriate drug duplications (n = 7 criteria), omissions of medications and/or medication associations (n = 16), medications with an unfavourable benefit/risk ratio and/or a questionable efficacy (n = 39), medications with an unsuitable dose (n = 4) or duration (n = 6), drug-disease (n = 13), and drug-drug interactions (n = 19). Conclusion The REMEDI[e]S tool (REview of potentially inappropriate MEDIcation pr[e]scribing in Seniors) is an original mixed tool, adapted to French medical practices, aimed at preventing PIP both at the individual level in clinical practice and the population level in large-scale studies. Therefore, its use could contribute to an improvement in healthcare professionals’ prescribing practices and safer care in older adults.


  • Open Access

    Association Between Antiangiogenic Drugs Used for Cancer Treatment and Artery Dissections or Aneurysms

    by Joris Guyon, Amandine Gouverneur, Sandy Maumus-Robert, Xavier Bérard, Antoine Pariente, Andreas Bikfalvi, Pernelle Noize

    Anticancer drugs targeting angiogenesis act either directly on vascular endothelial growth factor (VEGF) receptors (VEGF inhibitors) or VEGF-mediated intracellular processes (tyrosine kinase inhibitors) or indirectly through downstream VEGF signaling within broader processes (mammalian target of rapamycin inhibitors and multiprotein kinase inhibitors). Although VEGF blockade may be implicated in arterial wall injuries, the literature on the association between antiangiogenic drugs and artery dissections or aneurysms is scant, comprising only a few case reports and 1 pharmacovigilance study conducted in Japan.1 The present study evaluated the association between all antiangiogenic drugs and dissections or aneurysms occurring in all arteries.


  • Open Access

    The Burden of Potentially Inappropriate Medications in Chronic Polypharmacy

    by Jordan Guillot, Sandy Maumus-Robert, Alexandre Marceron, Pernelle Noize, Antoine Pariente, Julien Bezin

    We aimed to describe the burden represented by potentially inappropriate medications (PIMs) in chronic polypharmacy in France. We conducted a nationwide cross-sectional study using data from the French National Insurance databases. The study period was from 1 January 2016 to 31 December 2016. Chronic drug use was defined as uninterrupted daily use lasting ≥6 months. Chronic polypharmacy was defined as the chronic use of ≥5 medications, and chronic hyperpolypharmacy as the chronic use of ≥10 medications. For individuals aged ≥65 (older adults), PIMs were defined according to the Beers and Laroche lists, and for individuals aged 45–64 years (middle-aged) PIMs were defined according to the PROMPT (Prescribing Optimally in Middle-aged People’s Treatments) list. Among individuals with chronic polypharmacy, 4009 (46.2%) middle-aged and 18,036 (64.8%) older adults had at least one chronic PIM. Among individuals with chronic hyperpolypharmacy, these figures were, respectively, 570 (75.0%) and 2544 (88.7%). The most frequent chronic PIM were proton pump inhibitors (43.4% of older adults with chronic polypharmacy), short-acting benzodiazepines (older adults: 13.7%; middle-aged: 16.1%), hypnotics (6.1%; 7.4%), and long-acting sulfonylureas (3.9%; 12.3%). The burden of chronic PIM appeared to be very high in our study, concerning almost half of middle-aged adults and two-thirds of older adults with chronic polypharmacy. Deprescribing interventions in polypharmacy should primarily target proton pump inhibitors and hypnotics.


  • Overview of French databases available for studying anticancer drugs in real‐life setting

    by Emilie Casarotto, Pernelle Noize, Amandine Gouverneur, Driss Berdaï, Bernard Bégaud, Laurie Levy‐Bachelot, Mathieu Molimard

    Considering their novelty and cost, post‐marketing evaluation is highly relevant for new anticancer drugs. Identify and characterize available and potentially useful databases for post‐marketing evaluation of these specific drugs is necessary. A review was conducted to identify available and accessible databases to study the post‐marketing evaluation of drugs in real‐life care setting. Databases identified have been classified into medico‐administrative databases, medical record databases, and databases resulting from ad hoc collections. Taking as examples databases available in France, each type was described as well as its strengths and limits for a potential use in the oncology field. Record linkage of medico‐administrative databases could cover almost the whole population and is now used to evaluate anticancer drugs (e.g., Système National des Données de Santé). Large medical record databases are still lacking, but efforts are currently made to give access to hospital data warehouses for research purposes. Finally, databases resulting from ad hoc collections are also available for some cancer localizations and allow to obtain highly valuable clinical and biological data. A range of important and valuable databases exist but, individually, none is enough to answer to all questions from health authorities, healthcare professionals, and patients. In order to obtain a complete overview on utilization, associated health outcomes and costs of these drugs, it seems necessary to better interlink available databases.